Acadia Healthcare (ACHC)
(Delayed Data from NSDQ)
$55.80 USD
-0.91 (-1.60%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $55.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$55.80 USD
-0.91 (-1.60%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $55.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth A Momentum B VGM
Zacks News
Select Medical (SEM) Stock Down 6.6% Despite Q3 Earnings Beat
by Zacks Equity Research
Select Medical (SEM) continues to expect adjusted EBITDA to be between $795 million and $825 million in 2023.
Pediatrix (MD) Q3 Earnings Miss on High Costs, Shares Down 12%
by Zacks Equity Research
Pediatrix's (MD) third-quarter results suffer from the decline in same-unit revenues attributable to patient volume. Management currently expects 2023 adjusted EBITDA to be within $200-$210 million.
Zacks.com featured highlights Textron, Patterson-UTI Energy, ALLETE, Teekay Tankers and Acadia Healthcare
by Zacks Equity Research
Textron, Patterson-UTI Energy, ALLETE, Teekay Tankers and Acadia Healthcare have been highlighted in this Screen of The Week article.
Acadia Healthcare (ACHC) Q3 Earnings Beat on Patient Volumes
by Zacks Equity Research
Acadia Healthcare's (ACHC) Q3 results benefit from growth in patient days and revenue per patient day. Management forecasts adjusted EPS, excluding income from the PRF, of $3.33-$3.43 for 2023.
Why Acadia Healthcare (ACHC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
5 Low-Leverage Stocks to Buy as Inflation Fear Eases
by Aparajita Dutta
The crux of safe investment lies in choosing a company that is not burdened with debt as debt-free stock is almost impossible to find. You may buy TXT, PTEN, ALE, TNK and ACHC.
Humana (HUM) Q3 Earnings Beat on Strong Individual MA Unit
by Zacks Equity Research
Humana (HUM) continues to project 2023 adjusted EPS at a minimum of $28.25, which suggests growth from the 2022 figure of $25.88.
Tenet Healthcare (THC) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Tenet (THC) delivered earnings and revenue surprises of 20% and 1%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Community Health (CYH) Stock Down 1.7% Since Q3 Earnings Release
by Zacks Equity Research
Community Health (CYH) expects net operating revenues in the range of $12,400-$12,500 million for 2023.
Universal Health (UHS) Q3 Earnings Beat on Adjusted Patient Days
by Zacks Equity Research
Universal Health (UHS) has a leftover repurchase capacity of around $580 million as of Sep 30, 2023.
Universal Health Services (UHS) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Universal Health Services (UHS) delivered earnings and revenue surprises of 8.97% and 0.93%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Centene (CNC) Q3 Earnings Beat on Commercial Growth, View Raised
by Zacks Equity Research
Centene (CNC) anticipates adjusted EPS to register a minimum of $6.60 this year.
HCA Healthcare (HCA) Lags Q3 Earnings Estimates
by Zacks Equity Research
HCA (HCA) delivered earnings and revenue surprises of -1.51% and 2.80%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Does Acadia Healthcare (ACHC) Have the Potential to Rally 26.12% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.1% in Acadia Healthcare (ACHC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Humana (HUM) Boosts Healthcare Choices for MA Members in Denver
by Zacks Equity Research
Humana (HUM) enters into a deal with Denver Health to expand its local provider network across the Denver area as well as offer greater care access to its Medicare Advantage members of the region.
4 Undervalued Medical Stocks to Buy Amid High Market Volatility
by Indrajit Bandyopadhyay
Amid volatility, undervalued companies with solid prospects cushion investors from market jitters, while their robust fundamentals ensure higher returns. ACHC, PGNY, EGRX and NRBO are four such stocks.
All You Need to Know About Acadia Healthcare (ACHC) Rating Upgrade to Buy
by Zacks Equity Research
Acadia Healthcare (ACHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Down -11.71% in 4 Weeks, Here's Why You Should You Buy the Dip in Acadia Healthcare (ACHC)
by Zacks Equity Research
Acadia Healthcare (ACHC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Here's Why Investors Should Retain Acadia Healthcare (ACHC)
by Zacks Equity Research
Acadia Healthcare (ACHC) is well-poised for growth on the solid demand for behavioral healthcare services, the continuous pursuit of expansion initiatives and growing cash reserves.
Zacks Industry Outlook Highlights HCA Healthcare, Universal Health Services, Tenet Healthcare, Acadia Healthcare and Community Health Systems
by Zacks Equity Research
HCA Healthcare, Universal Health Services, Tenet Healthcare, Acadia Healthcare and Community Health Systems are part of the Zacks Industry Outlook article.
Implied Volatility Surging for Acadia Healthcare (ACHC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Acadia Healthcare (ACHC) stock based on the movements in the options market lately.
5 Hospital Stocks to Watch Amid Improving Industry Trends
by Kaibalya Pravo Dey
Cost optimization efforts and rising patient volumes for the Zacks Medical-Hospital industry players are major positives. HCA, UHS, THC, ACHC and CYH are poised to gain from improving occupancy rates.